Protocole National de Diagnostic et de Soins (PNDS) Schwannomatoses- non NF2

ARGUMENTAIRE

Centre constitutif labellisé des schwannomatoses

Mars 2025

Cet argumentaire a été élaboré par le centre de référence des schwannomatoses, sous la coordination du Pr. KALAMARIDES, Hôpital Pitié Salpêtrière. Il a servi de base à l'élaboration du PNDS Schwannonatoses Non NF2
Le PNDS est téléchargeable sur le site du centre de référence

Sommaire

Liste des abréviations **3**

Préambule **4**

Argumentaire **5**

1 Stratégie de rédaction du PNDS ..... Erreur ! Signet n
1.1 Agenda **Erreur ! Signet**
1.2 Ressources **Erreur ! Signet**

Annexe 1. Recherche documentaire et sélection des articles **7**

Annexe 2. Liste des participants **8**

Annexe 3. Autre ..... Erreur ! Signet n

Références bibliographiques ..... Erreur ! Signet n

Liste des abréviations

ALD	Affection de Longue Durée
AMM	Autorisation de Mise sur le Marché
PNDS	Protocole National de Diagnostic et de Soins

Préambule

Le PNDS sur les schwannomatoses non NF2 a été élaboré selon la « Méthode d'élaboration d'un protocole national de diagnostic et de soins pour les maladies rares » publiée par la Haute Autorité de Santé en 2012 (guide méthodologique disponible sur le site de la HAS : www.has-sante.fr). Le présent argumentaire comporte l'ensemble des données bibliographiques analysées pour la rédaction du PNDS.

Argumentaire

1 Stratégie de rédaction du PNDS

1.1 Agenda

Le PNDS concernant les Schwannomatoses non liées au gène NF2 a été rédigé tout au long de l'année 2024. L'agenda suivant a été défini initialement :

- Décembre 2023 : Définition du groupe de travail : désignation des participants des des différents centres de compétence et de référence, afin d'obtenir un quorum de spécialités nécessaire à la lecture critique de la bibliographie.
- Janvier 2024: Réunion préparatoire : visioconférence : validation du sommaire définitif, des responsables de la rédaction des différentes parties et la bibliographie de référence (arrêtée au 31/12/2023-Annexe 1).
- Février-Novembre 2024 : Rédaction de la PNDS par les différents référents de section
- Novembre 2024 : Réunion de révision du manuscrit : visioconférence
- Décembre 2024 : Finalisation de la rédaction du PNDS

La rédaction du PNDS s'est appuyée sur l'unique guide de bonnes pratiques publié en langue anglaise (Tableau 1) ainsi que sur la dernière revue de la littérature publiée par notre équipe (Tableau 2). En l'absence d'études cliniques de phase 1, 2 ou 3 réalisées dans la Schwannomatose non liée au gène NF2, le travail s'est uniquement appuyé sur les séries rétrospectives de la littérature et les études translationnelles liées à la maladie.

1.2 Ressources

Tableau 1. Recommandations de bonne pratique						
Auteur, année, référence, pays	**Objectif**	**Stratégie de recherche bibliographique renseignée (oui/non)***	**Recueil de l'avis des professionnels (non, oui, lesquels)**	**Recueil de l'avis des patients (non, oui)**	**Populations et techniques (ou produits) étudiées**	**Résultats (avec grade des recommandations si disponible)**
Evans 2022 **Royaume-Uni**	Recommendations de bonnes pratiques cliniques ERN GENTURIS	oui	Oui, panel international regroupant des professionnels anglais, français, belges et italiens	oui	Procédure Delphi	Série de recommandations sur les modalités de traitement et de surveillance de la Schwannomatose non liée au gène *NF2*

* date de début et fin de la recherche, bases de données, mots clés renseignés

Tableau 2. Revues systématiques de la littérature						
Auteur, année, référence, pays	**Objectif**	**Stratégie de recherche renseignée (oui/non)***	**Critères de sélection des études**	**Populations et techniques (ou produits) étudiées**	**Critères d'évaluation**	**Résultats et signification**
Planet, 2023, France	Revue actualisée de la littérature	oui	Impact pour la pratique clinique	Revue de la littérature	Impact clinique	Mise à jour

* date de début et fin de la recherche, bases de données, mots clés renseignés

Annexe 1. Recherche documentaire et sélection des articles

Recherche documentaire

Sources consultées	Bases de données : Pubmed Sites internet : CERENEF
Période de recherche	1996-2023
Langues retenues	Français, Anglais
Mots clés utilisés	Scwhwannomatosis
Nombre d'études recensées	601 études
Nombre d'études retenues	104 études

Critères de sélection des articles

Les articles ont été sélectionnés de façon à éliminer les articles traitant uniquement de la Schwannomatose liée à NF2 et les cas uniques sans apport supplémentaire pour la compréhension de la maladie.

Annexe 2. Liste des participants

Ce travail a été coordonné par le Pr. PEYRE, Centre de référence des schwannomatoses non NF2 (Service de Neurochirurgie, CHU Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital ; 75013 PARIS), sous la direction de (Pr. KALAMARIDES).

Ont participé à l'élaboration du PNDS :

Neurochirurgiens :

Pr Matthieu Peyre, Hôpital Pitié-Salpêtrière, Paris (Coordinateur)

Pr Rabih Aboukais, Hôpital Roger Salendro, Lille

Pr Denys Fontaine, Nice

Dr Vincent Jecko, Bordeaux

Pr Jean-Paul Lejeune, Hôpital Roger Salengro, Lille

Pr Dominique Liguro, Bordeaux

Pr Pierre-Hugues Roche, Hôpital Nord, Marseille

Pr Michel Kalamarides, Hôpital Pitié-Salpêtrière, Paris

ORL :

Christophe Vincent, Hôpital Roger Salengro, Lille

Neurologues : -

Pr Nadine ATTAL, Hôpital, Ambroise Paré, Boulogne

Pr François Ducray, Hôpital Pierre Wertheimer, Bron

Pr Jean-Pascal Lefaucheur, Hôpital Henri Mondor, Créteil

Dr Rachel Debs, Hôpital Purpan, Toulouse

Pr Marc Sanson, Hôpital Pitié-Salpêtrière, Paris

Dr Thierry Gendre, Hôpital Henri Mondor, Créteil

Généticiens :

Pr Béatrice Parfait, Hôpital Cochin, Paris

Dr Stéphane Pinson, Hôpital Pierre Wertheimer, Bron

Dr Cyril Goizet, CHU, Bordeaux

Dr Afane Brahimi, CHU, Lille

Dr Bertrand Isidor, CHU Hôtel Dieu, Nantes

Dr Delphine Dupin Deguine, CHU Purpan, Toulouse

Radiologue :

Dr Christophe Vandendries, Paris

Dermatologue :

Pr Pierre Wolkenstein, Hôpital Henri Mondor, Créteil

Dr Laura Fertitta, Hôpital Henri Mondor, Créteil

Pr Emmanuel Delaporte, Dermatologue, Marseille

Gestion des intérêts déclarés

Tous les participants à l'élaboration du PNDS sur les schwannomatoses non NF2 ont rempli une déclaration d'intérêt disponible sur le le site internet du centre de référence schwannomatoses.

Les déclarations d'intérêt ont été analysées et prises en compte, en vue d'éviter les conflits d'intérêts, conformément au guide HAS « Guide des déclarations d'intérêts et de gestion des conflits d'intérêts » (HAS, 2010).

Modalités de concertation du groupe de travail multidisciplinaire

Réunion initiale de mise en place : 25/01/2024

Réunion finale de revue du PNDS : 05/12/2024

Références bibliographiques

1. Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for *NF2*-related schwannomatosis. Smith MJ, Perez-Becerril C, van der Meer M, Burghel GJ, Waller SJ, Carney M, Bunstone S, Fryer K, Bowers NL, Hartley CL, Smith PT, Rutherford SA, Freeman SR, Lloyd SKW, Pathmanaban ON, King AT, Halliday D, Duff C, Evans DG. J Med Genet. 2024 Aug 29:jmg-2024-110217. doi: 10.1136/jmg-2024-110217.

2. *NF2*-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study.
Forde C, Smith MJ, Burghel GJ, Bowers N, Roberts N, Lavin T, Halliday J, King AT, Rutherford S, Pathmanaban ON, Lloyd S, Freeman S, Halliday D, Parry A, Axon P, Buttimore J, Afridi S, Obholzer R, Laitt R, Thomas O, Stivaros SM, Vassallo G, Evans DG. J Med Genet. 2024 Aug 29;61(9):856-860.

3. Coffin-Siris Syndrome and SMARCB1 Mutation Presenting With Schwannomatosis: A Case Report and Literature Review.
Gallagher JE, Saeed-Vafa D, Bui MM, Makanji R. Cureus. 2024 Aug 20;16(8):e67333. doi: 10.7759/cureus.67333.

4. Historical Development of Diagnostic Criteria for NF2-related Schwannomatosis.
Tamura R, Yo M, Toda M.Neurol Med Chir (Tokyo). 2024 Aug 15;64(8):299-308.

5. Heterozygosity for loss-of-function variants in LZTR1 is associated with isolated multiple café-au-lait macules.
Mastromoro G, Santoro C, Motta M, Sorrentino U, Daniele P, Peduto C, Petrizzelli F, Tripodi M, Pinna V, Zanobio M, Rotundo G, Bellacchio E, Lepri F, Farina A, D'Asdia MC, Piceci-Sparascio F, Biagini T, Petracca A, Castori M, Melis D, Accadia M, Traficante G, Tarani L, Fontana P, Sirchia F, Paparella R, Currò A, Benedicenti F, Scala I, Dentici ML, Leoni C, Trevisan V, Cecconi A, Giustini S, Pizzuti A, Salviati L, Novelli A, Zampino G, Zenker M, Genuardi M, Digilio MC, Papi L, Perrotta S, Nigro V, Castellanos E, Mazza T, Trevisson E, Tartaglia M, Piluso G, De Luca A. Genet Med. 2024 Aug 10;26(11):101241. doi: 10.1016/j.gim.2024.101241.

6. Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
Dhaenens BAE, Heimann G, Bakker A, Nievo M, Ferner RE, Evans DG, Wolkenstein P, Leubner J, Potratz C, Carton C, Iloeje U, Kirk G, Blakeley JO, Plotkin S, Fisher MJ, Kim A, Driever PH, Azizi AA, Widemann BC, Gross A, Parke T, Legius E, Oostenbrink R. Neurooncol Pract. 2024 Jan 4;11(4):395-403.

7. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.
Tamura R, Yamanobe Y, Fujioka M, Morimoto Y, Fukumura M, Nakaya M, Oishi Y, Sato M, Ueda R, Fujiwara H, Hikichi T, Noji S, Oishi N, Ozawa H, Ogawa K, Kawakami Y, Ohira T, Yoshida K, Toda M. J Clin Oncol. 2024 Jul 20;42(21):2578-2587.

8. Brigatinib in *NF2*-Related Schwannomatosis with Progressive Tumors.
Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, Bakker A, Fell G, Trippa L, Blakeley JO; INTUITT-NF2 Consortium. N Engl J Med. 2024 Jun 27;390(24):2284-2294.

9. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.
Kim BH, Chung YH, Woo TG, Kang SM, Park S, Kim M, Park BJ. Int J Mol Sci. 2024 Jun 14;25(12):6558.

10. High-frequency ultrasound imaging findings in the diagnosis of segmental schwannomatosis of the ulnar nerve: case report and literature review.
Li S, Han J, Zhang X, Qi Y, Du J, Zhao L. Skeletal Radiol. 2024 Mar 11.

11. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.

Merker VL, Gross AM, Widemann BC, Plotkin SR.
Clin Trials. 2024 Feb;21(1):3-5. doi: 10.1177/17407745231201345. Epub 2023 Sep 29.
PMID: 37776044 Free PMC article. No abstract available.

12. Somatic mosaic SOX10 indel mutations underlie a form of segmental schwannomatosis.
Terry M, Gupta R, Ravindranathan A, Wu J, Chan E, Bollen AW, Chang SM, Berger MS, Jacques L, Solomon DA.
Acta Neuropathol. 2023 Dec;146(6):857-860. doi: 10.1007/s00401-023-02641-6. Epub 2023 Oct 11.
PMID: 37821623 Free PMC article. No abstract available.

13. Schwannomatosis: a Realm Reborn: year one.
Planet M, Kalamarides M, Peyre M.
Curr Opin Oncol. 2023 Nov 1;35(6):550-557. doi: 10.1097/CCO.0000000000000994. Epub 2023 Sep 1.
PMID: 37820090 Review.

14. Surgical management of sporadic and schwannomatosis-associated pelvic schwannomas.
Peyre M, Gaudric J, Bernat I, André A, Couture T, Kalamarides M.
Neurosurg Rev. 2023 Oct 19;46(1):275. doi: 10.1007/s10143-023-02186-y.
PMID: 37857782

15. Whole body MRI with DWI in people with NF1 and Schwannomatosis: Are qualitative and quantitative imaging features of peripheral lesions comparable to localized MRI?
Debs P, Fayad LM, Romo CG, Ahlawat S.
Eur J Radiol. 2023 May;162:110802. doi: 10.1016/j.ejrad.2023.110802. Epub 2023 Mar 26.
PMID: 37001256

16. SMARCA4-associated schwannomatosis.
Chan-Pak-Choon F, Roca C, Chong AS, Nogué C, Dahlum S, Austin R, Mar Fan H, van Spaendonck-Zwarts KY, Lambie NK, Robertson T, Siebert R, Rivera B, Foulkes WD.
Acta Neuropathol. 2023 Apr;145(4):505-507. doi: 10.1007/s00401-023-02546-4. Epub 2023 Feb 14.
PMID: 36786840 No abstract available.

17. LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL.
Ko A, Hasanain M, Oh YT, D'Angelo F, Sommer D, Frangaj B, Tran S, Bielle F, Pollo B, Paterra R, Mokhtari K, Soni RK, Peyre M, Eoli M, Papi L, Kalamarides M, Sanson M, Iavarone A, Lasorella A.
Cancer Discov. 2023 Mar 1;13(3):702-723. doi: 10.1158/2159-8290.CD-22-0376.
PMID: 36445254

18. Screening of potential novel candidate genes in schwannomatosis patients.
Perez-Becerril C, Wallace AJ, Schlecht H, Bowers NL, Smith PT, Gokhale C, Eaton H, Charlton C, Robinson R, Charlton RS, Evans DG, Smith MJ.
Hum Mutat. 2022 Oct;43(10):1368-1376. doi: 10.1002/humu.24424. Epub 2022 Jun 27.
PMID: 35723634 Free PMC article.

19. Management of neurofibromatosis type 2 and schwannomatosis associated peripheral and intraspinal schwannomas: influence of surgery, genetics, and localization.
Gugel I, Grimm F, Tatagiba M, Schuhmann MU, Zipfel J.
J Neurooncol. 2022 Sep;159(2):271-279. doi: 10.1007/s11060-022-04061-0. Epub 2022 Jun 30.
PMID: 35771312 Free PMC article.

20. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Wolkenstein P, Evans DG.
Genet Med. 2022 Sep;24(9):1967-1977. doi: 10.1016/j.gim.2022.05.007. Epub 2022 Jun 9.
PMID: 35674741

21. Bibliometric analysis of the top 100 most-cited articles in neurofibromatosis.
Alnefaie N, Almutairi OT, Alturki AY, Bafaquh M.
Surg Neurol Int. 2022 Jul 1;13:282. doi: 10.25259/SNI_114_2022. eCollection 2022.
PMID: 35855179 Free PMC article. Review.

22. Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population.
Deng F, Evans DG, Smith MJ.
Hum Mutat. 2022 Jul;43(7):919-927. doi: 10.1002/humu.24376. Epub 2022 Apr 14.
PMID: 35391499 Free PMC article.

23. ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis.
Evans DG, Mostaccioli S, Pang D, Fadzil O Connor M, Pittara M, Champollion N, Wolkenstein P, Thomas N, Ferner RE, Kalamarides M, Peyre M, Papi L, Legius E, Becerra JL, King A, Duff C, Stivaros S, Blanco I.
Eur J Hum Genet. 2022 Jul;30(7):812-817. doi: 10.1038/s41431-022-01086-x. Epub 2022 Apr 1.
PMID: 35361920 Free PMC article.

24. Laminectomy triggers symptomatic growth of spinal schwannoma in a patient with schwannomatosis.
Oyama T, Nishimura Y, Nagashima Y, Nishii T, Hara M, Takayasu M, Sakakibara A, Saito R.
Surg Neurol Int. 2022 Jun 23;13:261. doi: 10.25259/SNI_453_2022. eCollection 2022.
PMID: 35855174 Free PMC article.

25. Spatial Distribution and Long-Term Alterations of Peripheral Nerve Lesions in Schwannomatosis.
Godel T, Bäumer P, Farschtschi S, Hofstadler B, Heiland S, Gelderblom M, Bendszus M, Mautner VF.
Diagnostics (Basel). 2022 Mar 23;12(4):780. doi: 10.3390/diagnostics12040780.
PMID: 35453828 Free PMC article.

26. Scrambler Therapy for the Treatment of Pain in Schwannomatosis.
Murphy T, Erdek M, Smith TJ.
Cureus. 2022 Mar 13;14(3):e23124. doi: 10.7759/cureus.23124. eCollection 2022 Mar.
PMID: 35464572 Free PMC article.

27. DGCR8 and the six hit, three-step model of schwannomatosis.
Nogué C, Chong AS, Grau E, Han H, Dorca E, Roca C, Mosquera JL, Lázaro C, Foulkes WD, Brunet J, Rivera B.
Acta Neuropathol. 2022 Jan;143(1):115-117. doi: 10.1007/s00401-021-02387-z. Epub 2021 Nov 25.
PMID: 34821987 No abstract available.

28. Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes.
Perez-Becerril C, Evans DG, Smith MJ.
Hum Mutat. 2021 Oct;42(10):1187-1207. doi: 10.1002/humu.24261. Epub 2021 Jul 29.
PMID: 34273915 Review.

29. Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE, Ferner RE, Evans DG, Heimann G, Potratz C, van de Ketterij E, Kaindl AM, Hissink G, Carton C, Bakker A, Nievo M, Legius E, Oostenbrink R.
Eur J Med Genet. 2021 Sep;64(9):104281. doi: 10.1016/j.ejmg.2021.104281. Epub 2021 Jul 5.
PMID: 34237445

30. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Merker VL, Lessing AJ, Moss I, Hussey M, Oberlander B, Rose T, Thalheimer R, Wirtanen T, Wolters PL, Gross AM, Plotkin SR; REiNS International Collaboration.
Neurology. 2021 Aug 17;97(7 Suppl 1):S4-S14. doi: 10.1212/WNL.0000000000012430. Epub 2021 Jul 6.
PMID: 34230208 Free PMC article.

31. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
Bettegowda C, Upadhayaya M, Evans DG, Kim A, Mathios D, Hanemann CO; REiNS International Collaboration.
Neurology. 2021 Aug 17;97(7 Suppl 1):S91-S98. doi: 10.1212/WNL.0000000000012436. Epub 2021 Jul 6.
PMID: 34230207 Free PMC article.

32. Surgical treatment of common peroneal neuropathy in schwannomatosis: illustrative cases.
North RY, Snyder R, Slopis JM, McCutcheon IE.
J Neurosurg Case Lessons. 2021 Jun 28;1(26):CASE21176. doi: 10.3171/CASE21176. eCollection 2021 Jun 28.
PMID: 35854908 Free PMC article.

33. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis.
Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR.

Patient Educ Couns. 2021 Apr;104(4):808-814. doi: 10.1016/j.pec.2020.09.029. Epub 2020 Sep 28.
PMID: 33051127 Free PMC article.

34. Diagnostic Pathology of Tumors of Peripheral Nerve.
Belakhoua SM, Rodriguez FJ.
Neurosurgery. 2021 Feb 16;88(3):443-456. doi: 10.1093/neuros/nyab021.
PMID: 33588442 Free PMC article. Review.

35. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Mansouri S, Suppiah S, Mamatjan Y, Paganini I, Liu JC, Karimi S, Patil V, Nassiri F, Singh O, Sundaravadanam Y, Rath P, Sestini R, Gensini F, Agnihotri S, Blakeley J, Ostrow K, Largaespada D, Plotkin SR, Stemmer-Rachamimov A, Ferrer MM, Pugh TJ, Aldape KD, Papi L, Zadeh G.
Acta Neuropathol. 2021 Jan;141(1):101-116. doi: 10.1007/s00401-020-02230-x. Epub 2020 Oct 6.
PMID: 33025139 Free PMC article.

36. Fluorescein-guided removal of peripheral nerve sheath tumors: a preliminary analysis of 20 cases.
Vetrano IG, Acerbi F, Falco J, Devigili G, Rinaldo S, Messina G, Prada F, D'Ammando A, Nazzi V.
J Neurosurg. 2019 Dec 6;134(1):260-269. doi: 10.3171/2019.9.JNS19970. Print 2021 Jan 1.
PMID: 31812148

37. Surgical Management of Multifocal Trigeminal Schwannomas.
Abou-Al-Shaar H, Cohen MA, Bi WL, Gozal YM, Alzhrani G, Karsy M, Al-Mefty O, Couldwell WT.
Oper Neurosurg (Hagerstown). 2020 Nov 16;19(6):659-666. doi: 10.1093/ons/opaa227.
PMID: 32717071

38. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
Radtke HB, Bergner AL, Goetsch AL, McGowan C, Panzer K, Cannon A.
J Genet Couns. 2020 Oct;29(5):692-714. doi: 10.1002/jgc4.1303. Epub 2020 Jun 29.
PMID: 32602153

39. Natural history of peripheral nerve schwannomas.
El Sayed L, Masmejean EH, Parfait B, Kalamarides M, Biau D, Peyre M.
Acta Neurochir (Wien). 2020 Aug;162(8):1883-1889. doi: 10.1007/s00701-020-04430-6. Epub 2020 Jun 16.
PMID: 32556523

40. Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.
Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A, Fröhling S.
J Clin Invest. 2020 May 1;130(5):2488-2495. doi: 10.1172/JCI130787.
PMID: 32017710 Free PMC article.

41. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S.
Acta Neuropathol. 2020 Apr;139(4):643-665. doi: 10.1007/s00401-019-02029-5. Epub 2019 Jun 4.
PMID: 31161239 Free PMC article. Review.

42. DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis.
Rivera B, Nadaf J, Fahiminiya S, Apellaniz-Ruiz M, Saskin A, Chong AS, Sharma S, Wagener R, Revil T, Condello V, Harra Z, Hamel N, Sabbaghian N, Muchantef K, Thomas C, de Kock L, Hébert-Blouin MN, Bassenden AV, Rabenstein H, Mete O, Paschke R, Pusztaszeri MP, Paulus W, Berghuis A, Ragoussis J, Nikiforov YE, Siebert R, Albrecht S, Turcotte R, Hasselblatt M, Fabian MR, Foulkes WD.
J Clin Invest. 2020 Mar 2;130(3):1479-1490. doi: 10.1172/JCI130206.
PMID: 31805011 Free PMC article. Clinical Trial.

43. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis.
Farschtschi SC, Kluwe L, Schön G, Friedrich RE, Matschke J, Glatzel M, Weis J, Hagel C, Mautner VF.
Brain Pathol. 2020 Mar;30(2):386-391. doi: 10.1111/bpa.12780. Epub 2019 Sep 12.
PMID: 31424590 Free PMC article.

44. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Ahlawat S, Blakeley JO, Langmead S, Belzberg AJ, Fayad LM.
Skeletal Radiol. 2020 Feb;49(2):199-219. doi: 10.1007/s00256-019-03290-1. Epub 2019 Aug 8.
PMID: 31396668 Review.

45. Extracapsular dissection in peripheral nerve schwannoma surgery using bright light and fluorescein sodium visualization: case series.
Kalamarides M, Bernat I, Peyre M.
Acta Neurochir (Wien). 2019 Dec;161(12):2447-2452. doi: 10.1007/s00701-019-04071-4. Epub 2019 Nov 2.
PMID: 31679103

46. Multiple primary malignancies associated with a germline SMARCB1 pathogenic variant.
Eelloo JA, Smith MJ, Bowers NL, Ealing J, Hulse P, Wylie JP, Shenjere P, Clarke NW, Soh C, Whitehouse RW, Jones M, Duff C, Freemont A, Gareth Evans D.
Fam Cancer. 2019 Oct;18(4):445-449. doi: 10.1007/s10689-019-00138-4.
PMID: 31240424

47. Segmental schwannomatosis: characteristics in 12 patients.
Alaidarous A, Parfait B, Ferkal S, Cohen J, Wolkenstein P, Mazereeuw-Hautier J.
Orphanet J Rare Dis. 2019 Aug 22;14(1):207. doi: 10.1186/s13023-019-1176-4.
PMID: 31438995 Free PMC article.

48. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.
Sanagoo A, Jouybari L, Koohi F, Sayehmiri F.
BMC Neurol. 2019 Jun 12;19(1):123. doi: 10.1186/s12883-019-1338-y.
PMID: 31189476 Free PMC article.

49. Malignant Peripheral Nerve Sheath Tumor Arising in Schwannomatosis with Multiple Lung Metastases.
Ding Y, Rong H, Liu T, Wang Y, Zhang J, Li S, Zhu T.
World Neurosurg. 2018 Nov;119:335-339. doi: 10.1016/j.wneu.2018.08.087. Epub 2018 Aug 23.
PMID: 30144611

50. Schwannomatosis: a genetic and epidemiological study.
Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, Lloyd SKW, Rutherford SA, Hammerbeck-Ward C, Pathmanaban ON, Freeman SR, Ealing J, Kellett M, Laitt R, Thomas O, Halliday D, Ferner R, Taylor A, Duff C, Harkness EF, Smith MJ.
J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1215-1219. doi: 10.1136/jnnp-2018-318538. Epub 2018 Jun 16.
PMID: 29909380

51. Management of multiple tumors in neurofibromatosis type 2 patients.
Aboukais R, Bonne NX, Baroncini M, Zairi F, Schapira S, Vincent C, Lejeune JP.
Neurochirurgie. 2018 Nov;64(5):364-369. doi: 10.1016/j.neuchi.2014.11.012. Epub 2015 Jun 10.
PMID: 26071178

52. Sporadic Schwannomatosis: A Systematic Review Following the 2005 Consensus Statement.
Chick G, Victor J, Poujade T, Hollevoet N.
J Neurol Surg A Cent Eur Neurosurg. 2018 Sep;79(5):408-415. doi: 10.1055/s-0038-1655548. Epub 2018 Jun 14.
PMID: 29902824 Review.

53. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
Kehrer-Sawatzki H, Kluwe L, Friedrich RE, Summerer A, Schäfer E, Wahlländer U, Matthies C, Gugel I, Farschtschi S, Hagel C, Cooper DN, Mautner VF.
Hum Genet. 2018 Jul;137(6-7):543-552. doi: 10.1007/s00439-018-1909-9. Epub 2018 Jul 13.
PMID: 30006736 Clinical Trial.

54. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschké P, Nectoux J, Orhant L, Zordan C, Goizet C, Goutagny S, Lallemand D, Vidaud M, Vidaud D, Kalamarides M, Parfait B.
Neuro Oncol. 2018 Jun 18;20(7):917-929. doi: 10.1093/neuonc/noy009.
PMID: 29409008 Free PMC article.

55. Dorsal root ganglia volume differentiates schwannomatosis and neurofibromatosis 2.
Godel T, Mautner VF, Farschtschi S, Pham M, Schwarz D, Kronlage M, Gugel I, Heiland S, Bendszus M, Bäumer

P.
Ann Neurol. 2018 Apr;83(4):854-857. doi: 10.1002/ana.25191. Epub 2018 Mar 25.
PMID: 29469988

56. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital.
Guha D, Davidson B, Nadi M, Alotaibi NM, Fehlings MG, Gentili F, Valiante TA, Tator CH, Tymianski M, Guha A, Zadeh G.
J Neurosurg. 2018 Apr;128(4):1226-1234. doi: 10.3171/2017.1.JNS162292. Epub 2017 Jul 7.
PMID: 28686119

57. Pain correlates with germline mutation in schwannomatosis.
Jordan JT, Smith MJ, Walker JA, Erdin S, Talkowski ME, Merker VL, Ramesh V, Cai W, Harris GJ, Bredella MA, Seijo M, Suuberg A, Gusella JF, Plotkin SR.
Medicine (Baltimore). 2018 Feb;97(5):e9717. doi: 10.1097/MD.0000000000009717.
PMID: 29384852 Free PMC article.

58. Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities.
Schulz A, Grafe P, Hagel C, Bäumer P, Morrison H, Mautner VF, Farschtschi S.
Exp Neurol. 2018 Jan;299(Pt B):334-344. doi: 10.1016/j.expneurol.2017.06.006. Epub 2017 Jun 3.
PMID: 28587874 Review.

59. Six cases of sporadic schwannomatosis: Topographic distribution and outcomes of peripheral nerve tumors.
Chick G, Victor J, Hollevoet N.
Hand Surg Rehabil. 2017 Oct;36(5):378-383. doi: 10.1016/j.hansur.2017.07.001. Epub 2017 Aug 3.
PMID: 28781128

60. Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development.
Vitte J, Gao F, Coppola G, Judkins AR, Giovannini M.
Nat Commun. 2017 Aug 21;8(1):300. doi: 10.1038/s41467-017-00346-5.
PMID: 28824165 Free PMC article.

61. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.
Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN.
Hum Genet. 2017 Feb;136(2):129-148. doi: 10.1007/s00439-016-1753-8. Epub 2016 Dec 5.
PMID: 27921248 Free PMC article. Review.

62. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
Talaei-Khoei M, Riklin E, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM.
J Neurooncol. 2017 Jan;131(2):413-419. doi: 10.1007/s11060-016-2314-7. Epub 2016 Nov 29.
PMID: 27900643

63. Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis.
Farschtschi S, Mautner VF, Pham M, Nguyen R, Kehrer-Sawatzki H, Hutter S, Friedrich RE, Schulz A, Morrison H, Jones DT, Bendszus M, Bäumer P.
Ann Neurol. 2016 Oct;80(4):625-8. doi: 10.1002/ana.24753. Epub 2016 Aug 13.
PMID: 27472264

64. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B; REiNS International Collaboration.
Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12. doi: 10.1212/WNL.0000000000002927.
PMID: 27527648 Free PMC article.

65. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016.
Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.
PMID: 27527647 Free PMC article.

66. Methylation-based classification of benign and malignant peripheral nerve sheath tumors.
Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-

Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, Perry A, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hänggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss DE.
Acta Neuropathol. 2016 Jun;131(6):877-87. doi: 10.1007/s00401-016-1540-6. Epub 2016 Feb 8.
PMID: 26857854

67. Hybrid Neurofibroma-Schwannoma.
Hussain NS, Specht CS, Frauenhoffer E, Glantz M, Harbaugh K.
Cureus. 2016 Mar 30;8(3):e548. doi: 10.7759/cureus.548.
PMID: 27158577 Free PMC article.

68. Neurofibromatosis type 2 (NF 2) or schwannomatosis?--Case report study and diagnostic criteria.
Radek M, Tomasik B, Wojdyn M, Snopkowska-Wiaderna D, Błaszczyk M, Radek A.
Neurol Neurochir Pol. 2016;50(3):219-25. doi: 10.1016/j.pjnns.2016.02.005. Epub 2016 Feb 23.
PMID: 27154453

69. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P, Zhao F, Zhang J, Wang Z, Wang X, Wang B, Yang Z, Yang J, Gao Z, Liu P.
J Neurosurg Spine. 2016 Jan;24(1):145-54. doi: 10.3171/2015.3.SPINE141145. Epub 2015 Sep 25.
PMID: 26407091

70. Immortalized Human Schwann Cell Lines Derived From Tumors of Schwannomatosis Patients.
Ostrow KL, Donaldson K, Blakeley J, Belzberg A, Hoke A.
PLoS One. 2015 Dec 14;10(12):e0144620. doi: 10.1371/journal.pone.0144620. eCollection 2015.
PMID: 26657314 Free PMC article.

71. Multiple Lower Extremity Mononeuropathies by Segmental Schwannomatosis: A Case Report.
Kwon NY, Oh HM, Ko YJ.
Ann Rehabil Med. 2015 Oct;39(5):833-7. doi: 10.5535/arm.2015.39.5.833. Epub 2015 Oct 26.
PMID: 26605183 Free PMC article.

72. The Long-term Outcome After Resection of Intraspinal Nerve Sheath Tumors: Report of 131 Consecutive Cases.
Halvorsen CM, Rønning P, Hald J, Johannesen TB, Kolstad F, Langmoen IA, Lied B, Skaar Holme S, Helseth E.
Neurosurgery. 2015 Oct;77(4):585-92; discussion 592-3. doi: 10.1227/NEU.0000000000000890.
PMID: 26191976

73. Commentary on: 'Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study'.
Hébert-Blouin MN, Spinner RJ.
J Plast Reconstr Aesthet Surg. 2015 Sep;68(9):1204-5. doi: 10.1016/j.bjps.2015.05.027. Epub 2015 May 29.
PMID: 26070489 No abstract available.

74. Expanding the mutational spectrum of LZTR1 in schwannomatosis.
Paganini I, Chang VY, Capone GL, Vitte J, Benelli M, Barbetti L, Sestini R, Trevisson E, Hulsebos TJ, Giovannini M, Nelson SF, Papi L.
Eur J Hum Genet. 2015 Jul;23(7):963-8. doi: 10.1038/ejhg.2014.220. Epub 2014 Oct 22.
PMID: 25335493 Free PMC article.

75. Expanding schwannomatosis phenotype.
Ioannidis P, Mamouli D, Foroglou N.
J Neurooncol. 2015 May;122(3):607-9. doi: 10.1007/s11060-015-1739-8. Epub 2015 Feb 8.
PMID: 25663272 No abstract available.

76. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
Castellanos E, Bielsa I, Carrato C, Rosas I, Solanes A, Hostalot C, Amilibia E, Prades J, Roca-Ribas F, Lázaro C, Blanco I, Serra E; NF2 Multidisciplinary Clinics HUGTiP-ICO-IMPPC.
BMC Med Genomics. 2015 Jan 24;8:2. doi: 10.1186/s12920-015-0076-2.
PMID: 25739810 Free PMC article.

77. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis.
Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, O'Sullivan J, Anderson B, Daly SB, Urquhart JE, Fryer A, Rustad CF, Mills SJ, Samii A, du Plessis D, Halliday D, Barbarot S, Bourdeaut F, Newman WG, Evans

DG.
Neurology. 2015 Jan 13;84(2):141-7. doi: 10.1212/WNL.0000000000001129. Epub 2014 Dec 5.
PMID: 25480913 Free PMC article.

78. Clinical response to bevacizumab in schwannomatosis.
Blakeley J, Schreck KC, Evans DG, Korf BR, Zagzag D, Karajannis MA, Bergner AL, Belzberg AJ.
Neurology. 2014 Nov 18;83(21):1986-7. doi: 10.1212/WNL.0000000000000997. Epub 2014 Oct 22.
PMID: 25339217 Free PMC article. No abstract available.

79. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants.
Hutter S, Piro RM, Reuss DE, Hovestadt V, Sahm F, Farschtschi S, Kehrer-Sawatzki H, Wolf S, Lichter P, von Deimling A, Schuhmann MU, Pfister SM, Jones DT, Mautner VF.
Acta Neuropathol. 2014 Sep;128(3):449-52. doi: 10.1007/s00401-014-1311-1. Epub 2014 Jul 10.
PMID: 25008767 No abstract available.

80. Surgical management of solitary nerve sheath tumors of the cervical spine: a retrospective case analysis based on tumor location and extension.
Abe J, Takami T, Naito K, Yamagata T, Arima H, Ohata K.
Neurol Med Chir (Tokyo). 2014;54(11):924-9. doi: 10.2176/nmc.oa.2014-0158. Epub 2014 Oct 31.
PMID: 25367583 Free PMC article.

81. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
Wolters PL, Martin S, Merker VL, Gardner KL, Hingtgen CM, Tonsgard JH, Schorry EK, Baldwin A; REiNS International Collaboration.
Neurology. 2013 Nov 19;81(21 Suppl 1):S6-14. doi: 10.1212/01.wnl.0000435747.02780.bf.
PMID: 24249806 Free PMC article. Review.

82. Schwannomatosis: the overlooked neurofibromatosis?
Koontz NA, Wiens AL, Agarwal A, Hingtgen CM, Emerson RE, Mosier KM.
AJR Am J Roentgenol. 2013 Jun;200(6):W646-53. doi: 10.2214/AJR.12.8577.
PMID: 23701098 Review.

83. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients.
Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M, Nagel C, Jeibmann A, Bohring A, Mautner VF, Paulus W.
Am J Surg Pathol. 2012 May;36(5):702-9. doi: 10.1097/PAS.0b013e31824d3155.
PMID: 22446939

84. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis.
Smith MJ, Wallace AJ, Bowers NL, Rustad CF, Woods CG, Leschziner GD, Ferner RE, Evans DG.
Neurogenetics. 2012 May;13(2):141-5. doi: 10.1007/s10048-012-0319-8. Epub 2012 Mar 22.
PMID: 22434358

85. Radiosurgery of spinal meningiomas and schwannomas.
Kufeld M, Wowra B, Muacevic A, Zausinger S, Tonn JC.
Technol Cancer Res Treat. 2012 Feb;11(1):27-34. doi: 10.7785/tcrt.2012.500231.
PMID: 22181328 Free PMC article.

86. Clinical features of schwannomatosis: a retrospective analysis of 87 patients.
Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR.
Oncologist. 2012;17(10):1317-22. doi: 10.1634/theoncologist.2012-0162. Epub 2012 Aug 27.
PMID: 22927469 Free PMC article.

87. Superficial neurofibromas in the setting of schwannomatosis: nosologic implications.
Rodriguez FJ, Scheithauer BW, George D, Midha R, MacCollin M, Stemmer-Rachamimov AO.
Acta Neuropathol. 2011 May;121(5):663-8. doi: 10.1007/s00401-010-0793-8. Epub 2010 Dec 30.
PMID: 21191601 Free PMC article.

88. Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. Clinical article.
Gonzalvo A, Fowler A, Cook RJ, Little NS, Wheeler H, McDonald KL, Biggs MT.
J Neurosurg. 2011 Mar;114(3):756-62. doi: 10.3171/2010.8.JNS091900. Epub 2010 Oct 8.
PMID: 20932094

89. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.
Rousseau G, Noguchi T, Bourdon V, Sobol H, Olschwang S.
BMC Neurol. 2011 Jan 24;11:9. doi: 10.1186/1471-2377-11-9.
PMID: 21255467 Free PMC article.

90. Polyradiculopathies from schwannomatosis.
Jia Y, Kraus JA, Reddy H, Groff M, Wong ET.
Open Neuroimag J. 2011;5:9-13. doi: 10.2174/1874440001105010009. Epub 2011 Jan 18.
PMID: 21643503 Free PMC article.

91. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, Rutherford SA, Trump D, Newman WG, Evans DG.
Oncogene. 2010 Nov 25;29(47):6216-21. doi: 10.1038/onc.2010.363. Epub 2010 Aug 23.
PMID: 20729918

92. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.
Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, Vivarelli R, Genuardi M, Papi L.
Neurogenetics. 2010 Feb;11(1):73-80. doi: 10.1007/s10048-009-0204-2. Epub 2009 Jul 7.
PMID: 19582488

93. Foraminal nerve sheath tumors: intermediate follow-up after cyberknife radiosurgery.
Murovic JA, Gibbs IC, Chang SD, Mobley BC, Park J, Adler JR Jr.
Neurosurgery. 2009 Feb;64(2 Suppl):A33-43. doi: 10.1227/01.NEU.0000341632.39692.9E.
PMID: 19165072

94. Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report.
Spinner RJ, Scheithauer BW, Perry A, Amrami KK, Emnett R, Gutmann DH.
J Neurosurg. 2007 Aug;107(2):435-9. doi: 10.3171/JNS-07/08/0435.
PMID: 17695403

95. Schwannomatosis in a patient with a pelvic mass: case report.
Harbaugh K, Smith P, Towfighi J.
Neurosurg Focus. 2007 Jun 15;22(6):E8. doi: 10.3171/foc.2007.22.6.9.
PMID: 17613225

96. Recognizing schwannomatosis and distinguishing it from neurofibromatosis type 1 or 2.
Westhout FD, Mathews M, Paré LS, Armstrong WB, Tully P, Linskey ME.
J Spinal Disord Tech. 2007 Jun;20(4):329-32. doi: 10.1097/BSD.0b013e318033ee0f.
PMID: 17538359

97. Germline mutation of INI1/SMARCB1 in familial schwannomatosis.
Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P.
Am J Hum Genet. 2007 Apr;80(4):805-10. doi: 10.1086/513207. Epub 2007 Feb 16.
PMID: 17357086 Free PMC article.

98. Increasing the specificity of diagnostic criteria for schwannomatosis.
Baser ME, Friedman JM, Evans DG.
Neurology. 2006 Mar 14;66(5):730-2. doi: 10.1212/01.wnl.0000201190.89751.41.
PMID: 16534111

99. Diagnostic criteria for schwannomatosis.
MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES.
Neurology. 2005 Jun 14;64(11):1838-45. doi: 10.1212/01.WNL.0000163982.78900.AD.
PMID: 15955931 Review.

100. Familial schwannomatosis: exclusion of the NF2 locus as the germline event.
MacCollin M, Willett C, Heinrich B, Jacoby LB, Acierno JS Jr, Perry A, Louis DN.
Neurology. 2003 Jun 24;60(12):1968-74. doi: 10.1212/01.wnl.0000070184.08740.e0.
PMID: 12821741

101. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis?

Leverkus M, Kluwe L, Röll EM, Becker G, Bröcker EB, Mautner VF, Hamm H.
Br J Dermatol. 2003 Apr;148(4):804-9. doi: 10.1046/j.1365-2133.2003.05249.x.
PMID: 12752143

102. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2?
Seppälä MT, Sainio MA, Haltia MJ, Kinnunen JJ, Setälä KH, Jääskeläinen JE.
J Neurosurg. 1998 Jul;89(1):36-41. doi: 10.3171/jns.1998.89.1.0036.
PMID: 9647170

103. Schwannomatosis: a clinical entity distinct from neurofibromatosis type 2.
Wolkenstein P, Benchikhi H, Zeller J, Wechsler J, Revuz J.
Dermatology. 1997;195(3):228-31. doi: 10.1159/000245948.
PMID: 9407167

104. Schwannomatosis: a clinical and pathologic study.
MacCollin M, Woodfin W, Kronn D, Short MP.
Neurology. 1996 Apr;46(4):1072-9. doi: 10.1212/wnl.46.4.1072.
PMID: 8780094 Review.